

## Non-isothermal thermogravimetry as an accelerated tool for the shelf-life prediction of paracetamol formulations

Martina Maria Calvino<sup>a</sup>, Lorenzo Lisuzzo<sup>a</sup>, Giuseppe Cavallaro<sup>a,b,\*</sup>, Giuseppe Lazzara<sup>a,b</sup>, Stefana Milioto<sup>a,b</sup>

<sup>a</sup>*Dipartimento di Fisica e Chimica, Università degli Studi di Palermo, Viale delle Scienze, pad. 17, 90128 Palermo, Italy. giuseppe.cavallaro@unipa.it*

<sup>b</sup>*Consorzio Interuniversitario Nazionale per la Scienza e Tecnologia dei Materiali, INSTM, Via G. Giusti, 9, I-50121 Firenze, Italy*

### Abstract

In this work, non-isothermal thermogravimetric studies have been carried out on several paracetamol formulations with the aim to predict their shelf-lives under variable storage conditions. Specifically, paracetamol tablets of different brands have been investigated allowing to estimate their pharmaceutical quality by considering the specific drug stability. The proposed protocol is based on the kinetic study of thermogravimetric data by the combination of isoconversional procedures (Friedman and Kissinger-Akahira-Sunose (KAS) methods) and “Master plot” analysis. Accordingly, the kinetics of the paracetamol degradation is totally explored in terms of activation energy, pre-exponential factor and reaction mechanism of the drug decomposition. The obtained insights drive to simulate the decay time functions of paracetamol amount for the several pharmaceutical formulations. Interestingly, these simulations can be easily adapted to variable isothermal conditions providing the shelf-lives of the paracetamol tablets at different temperatures. The kinetic characteristics of the paracetamol degradation as well as the corresponding shelf-life values evidenced that the expiration date of the pharmaceutical products are significantly affected by the composition of the excipients. In conclusion, this work demonstrates that non-isothermal thermogravimetric analysis can be used as efficient and sensitive tool for the prediction of the shelf-lives of paracetamol formulations.

**Keywords:** Shelf-life, thermogravimetry; isoconversional methods, paracetamol.

## 1. Introduction

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Pharmaceutical products are obtained as mixtures of active molecules and several excipients, which control the workability, the stability and the release properties of the formulations [1–3]. The actual shelf life of the active molecules represents a key parameter of the pharmaceutical quality of drug products [4,5]. Therefore, the accurate estimation of the drug shelf-life is challenging in the pharmaceutical technologies [6,7]. It should be noted that the shelf-life corresponds to the time after which the drug loses its properties and it cannot perform its function efficiently because of decomposition or structural changes, which depend on several factors, including dehydration, oxidation and microbial spoilage [8]. The shelf-life determination of the drugs can be conducted by accelerated degradation conditions avoiding to study the entire real-time decomposition [9,10]. As reported in a recent review [11], acceleration studies on the chemical degradation of several materials can be performed by thermal analysis and calorimetry techniques. In this regard, thermogravimetry represents a powerful method to estimate the oxidative stability of vegetable oils [12] and to predict the life time of polymeric materials used in technological applications [13–15]. Within pharmaceuticals, thermogravimetric analysis was used to determine the shelf-life of vitamin C under both inert and oxidative conditions [16]. Moreover, thermogravimetry was employed to investigate the thermal stability of drug molecules encapsulated into polymeric nanoparticles [17,18], cyclodextrins [19,20] and inorganic mesoporous materials [21–28]. The influence of the excipients in the shelf-life of the active molecules plays a crucial role in the development of pharmaceutical formulations. Any unintended variations of the inherent nature and physicochemical characteristics of the excipients could lead to potential instabilities in the formulations [29,30]. In addition, both physical and chemical interactions between drugs and excipients can affect the stability [31] as well as the porosity of the pharmaceutical products [32]. Literature reports that the excipients can significantly alter the properties and functionalities of paracetamol. As examples, the presence of povidone could generate severe allergy [33], while excipients containing trehalose and melibiose affect the crystallization of the drug molecules [34]. The degradation of paracetamol can be influenced

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

by several processes, such as peroxy monosulfate activation reactions [35] and catalytic actions of iron oxide nanostructures [36] or black TiO<sub>2</sub> as photocatalysts [37]. The thermal stability of paracetamol depends on the polymorphs of the drug molecules [38] as well as on the presence of impurities in the pharmaceutical products [39].

In this study, the thermal degradation of various paracetamol tablets from different brands was investigated by thermogravimetry. In particular, thermogravimetric experiments were conducted at variable heating rate to explore the kinetics of paracetamol degradation through non isothermal isoconversional methods. As reported in literature, different isoconversional procedures are suitable to study the kinetic aspects of the polymer decomposition in nanocomposite materials [40–43], polymer blends [44,45], ionic liquids [46,47] and bioactive molecules [16,48,49]. Here, Kissinger-Akahira-Sunose (KAS) and Friedman methods were employed as non-isothermal and model-free procedures providing the activation energy of the degradation processes without any assumption on the reaction mechanism [50]. Consequently, they are widely used in kinetic studies of thermal decomposition of macromolecules [51–54]. Furthermore, the Master plot analysis was employed to determine the mechanism of the paracetamol degradation allowing to estimate the shelf-life of the pharmaceutical products.

## 2. Materials and methods

### 2.1 Materials

Several paracetamol tablets from different pharmaceutical companies were analyzed. Prior to their analysis by thermogravimetry, the tablets were treated in an agate mortar to obtain homogeneous powder samples. The properties of the paracetamol formulations are listed in Table 1.

**Table 1.** List of paracetamol formulations

Sample ID	Country	Excipients	Excipients (wt%)
<b>US</b>	United States of America	Carnauba wax	11.85
		Polyvinylpyrrolidone	
		PEG	
		Sodium Croscarmellose	
		Stearic Acid	
		Hypromellose Jelly	
<b>IT 1</b>	Italy	Sodium Starch Glycolate	6.72
		Potato starch	
		Magnesium stearate	
<b>BR</b>	Brazil	Polyvinylpyrrolidone	12.29
		Polyvinylpyrrolidone	
		Sodium Starch Glycolate	
		Starch	
		Stearic Acid	
		Polyvinyl Alcohol	
<b>RO</b>	Romania	Macrogol	16.25
		Talc	
		Titanium Dioxide	
		Corn Starch	
		Povidone K30	
		Colloidal silica	
<b>RU</b>	Russian Federation	Anhydrous Magnesium Stearate	9.17
		Talc	
		Potato starch	
		Polyvinylpyrrolidone (low molecular weight)	
		Stearic Acid	
<b>IT 2</b>	Italy	Magnesium stearate	4.9
		Microcrystalline Cellulose	
		Pregelatinized Starch	
		Stearic Acid	
		Sodium Croscarmellose	
		Polyvinylpyrrolidone	

### 2.2 Methods

Thermogravimetric experiments were performed by using a Q5000 IR apparatus (TA Instruments) under inert atmosphere. To this purpose, the measurements were conducted under nitrogen flows of


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

25 and 10 cm<sup>3</sup> min<sup>-1</sup> for the sample and the balance, respectively. The weight of each sample was ca. 5 mg. The temperature calibration was carried out using the Curie temperatures of several standards (cobalt, nickel and their alloys) as reported elsewhere [51,54]. To determine the kinetics of degradation, the tests were carried out by heating the sample from room temperature to 400 °C at variable heating rates ( $\beta$ ). In detail, heating rates of 2, 5, 10, 15 and 20 °C min<sup>-1</sup> were selected. The preliminary analysis of the thermogravimetric curves provided the following parameters: 1) residual mass at 400 °C (RM<sub>400</sub>); 2) onset temperature (T<sub>onset</sub>); 3) decomposition temperature (T<sub>max</sub>) taken at the maximum of the first order derivative curves of mass loss to temperature (DTG curves). Kinetic analysis of the thermogravimetric data was conducted by using KAS and Friedman methods in order to determine the activation energies (E<sub>α</sub>) of the paracetamol degradation at variable conversion degree ( $\alpha$ ), which was calculated as  $(m_0 - m)/(m_0 - m_\infty)$  being  $m_0$  the initial mass,  $m$  the mass at time  $t$  e  $m_\infty$  the residual mass. Both isoconversional procedures were employed within the  $\alpha$  range between 0.1 and 0.9. Finally, the thermogravimetric results were investigated through the Master plot analysis driving to the determination of the shelf-life of the paracetamol formulations.

### 3. Results and Discussion

#### 3.1 Thermal degradation under nitrogen atmosphere.

Thermogravimetric analysis is a powerful method to investigate the degradation of materials under controlled atmospheres upon a given heating ramp. The thermal stability of composites [55], polymers [56] and pharmaceuticals formulations [57] can be evidenced by comparing the thermogravimetric curves in terms of T<sub>onset</sub> and residual mass values. This strategy is typically successful and it endows comparisons and assessments when systematic changes in internal/external parameters are targeted. As an example, Figure 1 shows the thermogravimetric curves at variable heating rate for the BR sample. Supporting Information shows the thermogravimetric curves collected for the other paracetamol tablets as well as the DTG curves at variable heating rates for the BR formulation.



**Fig. 1.** Thermogravimetric curves of BR sample obtained at variable heating rates.

As a general result, the thermogravimetric curves evidenced a mass loss within the temperature range between 150 and 320 °C due to the paracetamol degradation. It should be noted that the increase of the heating rate shifts the paracetamol decomposition to larger temperatures. For a quantitative comparison of the several paracetamol formulations, we calculated the values of  $T_{\max}$ ,  $T_{\text{onset}}$  and residual mass at 400 °C for each sample by considering the heating rate of  $10^{\circ}\text{C min}^{-1}$  (Table 2).

**Table 2.** Thermogravimetric parameters of the paracetamol formulations obtained at  $\beta$  of  $10^{\circ}\text{C min}^{-1}$ .

Sample ID	$T_{\max}$ [°C]	$T_{\text{onset}}$ [°C]	RM <sub>400</sub> [%]
US	$271 \pm 3$	$232 \pm 2$	$3.28 \pm 0.03$
IT 1	$281 \pm 3$	$246 \pm 2$	$3.79 \pm 0.03$
BR	$279 \pm 3$	$241 \pm 2$	$9.10 \pm 0.09$
RO	$274 \pm 3$	$235 \pm 2$	$7.87 \pm 0.08$
RU	$262 \pm 3$	$228 \pm 2$	$8.12 \pm 0.08$
IT 2	$264 \pm 3$	$231 \pm 2$	$6.03 \pm 0.06$

We observed that the paracetamol tablets possess different  $T_{\text{onset}}$  and  $T_{\max}$  values within intervals of ca. 20 °C. These results highlight that the amount and the composition of the excipients can affect

1 the thermal degradation process of paracetamol. The variations of the residual masses at 400 °C  
 2 (Table 2) reflects the different chemical composition of the excipients. In particular, we estimated  
 3  
 4 larger  $RM_{400}$  values for the tablets containing inorganic excipients, which decompose at temperatures  
 5  
 6 higher than 400 °C. Similar observations were detected for levothyroxine formulations [58]. The  
 7  
 8 comparison of the thermogravimetric results obtained from a single heating ramp represents a  
 9  
 10 preliminary analysis, which cannot drive to quantitative conclusions on the shelf-life differences  
 11  
 12 among the paracetamol formulations. To this purpose, a further and deeper analysis of the  
 13  
 14 thermogravimetric data is necessary. In this regard, we determined the kinetic parameters of the  
 15  
 16 paracetamol degradation in the different tablets by using non isothermal isoconversional methods.  
 17  
 18  
 19  
 20  
 21  
 22  
 23

### 24 **3.2 Isoconversional methods and kinetic parameters.**

25  
 26 Thermogravimetric curves at variable heating rates ( $\beta$ ) were analyzed by isoconversional procedures  
 27  
 28 (KAS and Friedman methods) with the aim to investigate the kinetics of the paracetamol degradation  
 29  
 30 in the different pharmaceutical formulations.  
 31  
 32

33  
 34 Friedman differential method [59] is based on the following equation


$$35 \ln \left( \beta \frac{d\alpha}{dT} \right)_{\alpha,i} = \ln[f(\alpha)A_{\alpha}] - \frac{E_{\alpha}}{RT_{\alpha,i}} \quad (1)$$

36  
 37 where  $d\alpha/dT$  is the first derivative of  $\alpha$  respect to temperature,  $f(\alpha)$  is a function of the extent of  
 38  
 39 conversion,  $A$  is the pre-exponential factor,  $R$  is the gas constant and  $T$  is the absolute temperature.  
 40  
 41 The subscript  $i$  refers to the various heating rates. On this basis,  $T_{\alpha,i}$  corresponds to the temperature  
 42  
 43 with a certain extent of conversion under a selected heating rate.  $E_a$  values at different  $\alpha$  were obtained  
 44  
 45 from the slope of the  $\ln(\beta d\alpha/dT)$  vs  $1/T$  plots.  
 46  
 47  
 48  
 49  
 50  
 51

52  
 53 On the other hand, KAS approach [60] is an integral isoconversional procedure, which can be  
 54  
 55 expressed as  
 56

$$57 \ln \left( \frac{\beta_i}{T_{\alpha,i}^2} \right) = Cost - \frac{E_{\alpha}}{RT_{\alpha}} \quad (2)$$

According to equation 2,  $E_\alpha$  values at different  $\alpha$  can be calculated from the slope of  $\ln(\beta/T^2)$  vs  $1/T$  plots. The  $E_\alpha$  vs  $\alpha$  trends obtained by both Friedman and KAS method are presented in Figure 2.



**Fig. 2.** Activation energy as a function of the conversion degree obtained from Friedman (a) and KAS (b) methods.

Based on the ICTAC recommendations [61], the activation energy can be considered constant within the whole conversion degree range for all paracetamol formulations being that the difference between the maximum and minimum values of  $E_\alpha$  is less than 20-30% of the average  $E_\alpha$  value. On this basis, we can state that the paracetamol degradation is a single stage process. The averaged activation energies obtained from both procedures are presented in Table 3.




**Table 3.** Average activation energies obtained from Friedman and KAS methods.

Sample ID	Friedman [kJ mol <sup>-1</sup> ]	KAS [kJ mol <sup>-1</sup> ]
<b>US</b>	120 ± 12	124 ± 8
<b>IT 1</b>	93 ± 16	90 ± 16
<b>BR</b>	97 ± 22	98 ± 22
<b>RO</b>	117 ± 7	121 ± 7
<b>RU</b>	71 ± 10	72 ± 12
<b>IT 2</b>	100 ± 6	105 ± 6

We observed that KAS and Friedman methods provided similar average activation energies highlighting the robustness of both integral and differential isoconversional procedures in the kinetic analysis of paracetamol degradation. It should be noted that the activation energy reflects the thermal stability of the drug molecules. The estimation of the activation energy values represents the first step in the kinetic analysis of the thermogravimetric data. Notwithstanding, the determination of the full kinetics path is necessary for any shelf-life prediction. With this in mind the Master plot method developed by J. Malek [62] was used to determine the reaction mechanism. To this purpose, the function  $z(\alpha)$  was calculated by using the following equation

$$z(\alpha) = f(\alpha)g(\alpha) = \left(\frac{d\alpha}{dt}\right)_\alpha T_\alpha^2 \quad (3)$$

The experimental values of  $z(\alpha)$  are plotted as a function of  $\alpha$  and compared to the theoretical master plots reported in literature [61]. As an example, the experimental  $z(\alpha)$  vs  $\alpha$  plot for the IT2 tablet is provided in Figure 3. We observed that a maximum is reached at  $\alpha$  equals to ca. 0.75.



**Fig. 3.** “Master plot” analysis for the IT2 sample presented as  $z(\alpha)$  vs  $\alpha$  plots (experimental and theoretical). The theoretical  $z(\alpha)$  vs  $\alpha$  plot is based on the R2 mechanism. The coefficient of determination ( $R^2$ ) between experimental and theoretical curves is 0.985.

Similar  $z(\alpha)$  vs  $\alpha$  trends (see Supporting Information) were detected for the other paracetamol formulations. According to literature [61,63], the obtained  $z(\alpha)$  vs  $\alpha$  plots can be ascribed to the R2 mechanism (contracted cylindrical geometry) for the paracetamol degradation. As shown in Figure 3, the experimental  $z(\alpha)$  vs  $\alpha$  plot for the IT2 sample is properly described by the theoretical  $z(\alpha)$  vs  $\alpha$  function based on the R2 model. We estimated the goodness of the fit between experimental and theoretical curves by the determination of the coefficient of the determination ( $R^2$ ). We observed that the  $R^2$  value is 0.985 for the IT2 sample. Supporting Information shows that R2 model is proper for the description of the  $z(\alpha)$  vs  $\alpha$  trends for all the paracetamol formulations. The  $R^2$  values range between 0.958 and 0.982 highlighting that the data analysis by R2 model is accurate. As a general result, we estimated lower  $R^2$  values by fitting  $z(\alpha)$  vs  $\alpha$  plots with different theoretical models. Accordingly, we can state that R2 is the best kinetic model for the description of the paracetamol degradation. It should be noted that R2 model assumes that the degradation starts at the surface. The

degradation rate is affected by the resulting interface reaction progress from the surface toward the centre [64]. Based on R2 model,  $f(\alpha)$  can be expressed as

$$f(\alpha) = 2(1 - \alpha)^{\frac{1}{2}} \quad (4)$$

Based on the activation energies (Table 3) and taking into account that all the tablets present the same degradation mechanism, US and RU samples can be considered the most stable formulations, while RU sample presents the slightest resistance to the thermal degradation of paracetamol.

According to the R2 mechanism, the pre-exponential factor (A) of the paracetamol decomposition can be determined by fitting the experimental data with the following equation

$$y(\alpha) = \left(\frac{d\alpha}{dt}\right)_\alpha \exp\left(\frac{E_0}{RT_\alpha}\right) = A 2(1 - \alpha)^{\frac{1}{2}} \quad (5)$$

where  $E_0$  represents the average activation energies (Table 3) determined from the isoconversional procedures. As evidenced in Table 4, the pre-exponential factor of the paracetamol degradation is significantly dependent on the specific pharmaceutical formulation. The latter can be related to different amounts and composition of the excipients containing in the paracetamol tablets.

**Table 4.** Pre-exponential factor values obtained from Friedman and KAS methods.

Sample ID	A [s <sup>-1</sup> ] (Friedman method)	A [s <sup>-1</sup> ] (KAS method)
US	(151 ± 5) · 10 <sup>8</sup>	(280 ± 9) · 10 <sup>8</sup>
IT 1	(46 ± 5) · 10 <sup>5</sup>	(28 ± 3) · 10 <sup>5</sup>
BR	(110 ± 3) · 10 <sup>5</sup>	(130 ± 3.3) · 10 <sup>5</sup>
RO	(35.0 ± 1.1) · 10 <sup>8</sup>	(94 ± 3) · 10 <sup>8</sup>
RU	(15 ± 6) · 10 <sup>3</sup>	(16 ± 7) · 10 <sup>3</sup>
IT 2	(110 ± 4) · 10 <sup>6</sup>	(31.0 ± 1.0) · 10 <sup>7</sup>

1 The determination of the pre-exponential factors, activation energies and the reaction mechanism  
2 allowed us to completely describe the kinetics of the paracetamol degradation. These findings can be  
3  
4 exploited to predict the shelf-life of paracetamol tablets under variable storage conditions.  
5  
6  
7

### 8 9 **3.3 Shelf-life prediction**


10  
11 Based on the calculated kinetic parameters, we can estimate the time ( $t_\alpha$ ) required to achieve a certain  
12  
13 degree of degradation under isothermal conditions. Specifically,  $t_\alpha$  can be calculated by the  
14  
15 following equation:  
16  
17

$$18 \quad t_\alpha = \frac{g(\alpha)}{A \exp\left(-\frac{E}{RT_0}\right)} \quad (6)$$

19  
20  
21  
22  
23  
24  
25  
26  
27 where  $T_0$  is the fixed temperature, while  $g(\alpha)$  is a function dependent on the specific reaction  
28  
29 mechanism. According to the R2 mechanism,  $g(\alpha)$  can be expressed as [61]  
30  
31

$$32 \quad g(\alpha) = 1 - (1 - \alpha)^{\frac{1}{2}} \quad (7)$$


33  
34  
35  
36  
37 Equations 6 and 7 allowed us to determine the simulated  $t_\alpha$  vs  $\alpha$  curves for the paracetamol  
38  
39 formulations. It should be noted that the kinetic parameters calculated from KAS method were used.  
40  
41 As examples, Figure 4 shows the  $t_\alpha$  vs  $\alpha$  functions for BR sample at three different temperatures (4,  
42  
43 25 and 40 °C).  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



**Fig. 4.** Simulated  $t_\alpha$  vs  $\alpha$  curves for BR sample at 4, 25 and 40 °C. The functions were determined according to equations 6 and 7. Dotted line represents  $\alpha = 0.1$ .

As reported in literature [65,66], the shelf-life of pharmaceutical products can be defined as the time required for the drug to degrade more than 10% of its original amount. Accordingly, we estimated the shelf-life of paracetamol formulations by determining the  $t_\alpha$  values at  $\alpha = 0.1$ . As shown in Figure 4, the shelf-life at variable temperatures can be easily detected from the simulated  $t_\alpha$  vs  $\alpha$  curves.

Figure 5 illustrates the shelf-lives of the paracetamol tablets under variable temperatures (4, 25 and 40 °C), which mime different storage conditions of the pharmaceutical products. The corresponding  $t_\alpha$  values are presented in Supporting Information. Note that the reported values refer to the KAS method.



**Fig. 5.** Shelf-lives of paracetamol formulations at 4, 25 and 40 °C. The data were determined by the simulations of  $t_{\alpha}$  vs  $\alpha$  functions obtained using the kinetic parameters from KAS method.

Comparing the six paracetamol formulations, the estimated shelf-lives show the same trend of the activation energies. The latter is consistent with the paracetamol degradation mechanism (R2), which is equivalent for all the tablets. As expected, the temperature increase determines a significant

1 reduction of the shelf-life for all the samples. We detected that US and RO formulations exhibits  
2 larger stability compared to the other formulations. Comparing the data at 40 °C, we calculated shelf-  
3 lives of 4 and 6 years for RO and US samples. On the other hand, RU tablet exhibited shelf-lives of  
4 8.4 and 3.6 months at 25 and 40 °C, respectively. These values are shorter with respect to the normal  
5 shelf-lives stated by the manufacturers. The products from Italy and Brazil evidenced similar  
6 characteristics with shelf-lives in the range 36-54 months at 25 °C. It should be noted that the  
7 calculated results are obtained by thermogravimetric experiments conducted under nitrogen flows.  
8 Therefore, the shelf-lives presented in Figure 5 can be considered for tablets stored in inert  
9 atmosphere. The obtained results can be used to evaluate the pharmaceutical quality of the  
10 investigated products as well as the preferential storage conditions for the different formulations.  
11 Within this, the storage of the RU tablet in the refrigerator at 4°C (shelf-life of 48 months) could  
12 guarantee similar characteristics (in terms of efficacy and the safety) of other paracetamol  
13 formulations (IT1, IT2, BR) stored at room temperature.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

#### 34 **4. Conclusions**

35  
36 We propose non-isothermal thermogravimetry as accelerated tool to estimate the shelf-life of  
37 paracetamol tablets. Specifically, the study was conducted on commercial formulations produced  
38 from various pharmaceutical industries worldwide. The protocol consists of three steps: 1)  
39 preliminary analysis of the thermogravimetric curves at a fixed heating ramp; 2) kinetic analysis of  
40 thermogravimetric data collected at five variable heating rates in order to totally describe the kinetics  
41 of paracetamol decomposition for all the tablets. In this regard, activation energies and pre-  
42 exponential factor values were successfully estimated from isoconversional procedures (Friedman  
43 and KAS methods) and “Master plot” analyses, respectively; 3) simulations of the decay time  
44 functions of paracetamol at variable temperatures (4, 25 and 40 °C). We observed that the formulation  
45 produced in Russian Federation possesses the lowest stability. In particular, we calculated shelf-lives  
46 of 3.6, 8.4 and 48 months at 4, 25 and 40 °C, respectively. The American formulation exhibited the  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 largest stability with shelf-lives of ca. 1 order larger with respect to those of the Russian sample. The  
2 formulation produced in Italy and Brazil evidenced intermediate shelf-lives, which range between 36  
3 and 54 months at storage temperature of 25 °C. The different stability of the paracetamol is related  
4 and 54 months at storage temperature of 25 °C. The different stability of the paracetamol is related  
5 to peculiar composition of the excipients in the formulations. It should be noted that the mentioned  
6 results were calculated in inert atmosphere without any stress inputs in terms of humidity variations  
7 and light and/or oxygen exposure.  
8  
9  
10  
11  
12

13 In conclusion, this work evidenced that kinetic studies by non-isothermal thermogravimetry are  
14 suitable to determine the shelf-lives of paracetamol tablets under accelerated conditions. The  
15 proposed protocol might be adapted to investigate the quality of pharmaceutical products under  
16 variable storage conditions.  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 **Acknowledgments.** The work was financially supported by the University of Palermo.  
27  
28  
29  
30

31 **Supporting Information:** Thermogravimetric curves at variable heating rates for US, IT1, IT2, RO  
32 and RU tablets. Differential thermogravimetric curves at variable heating rates for BR, US, IT1, IT2,  
33 RO and RU tablets. Master plot analysis (presented as experimental and theoretical  $z(\alpha)$  vs  $\alpha$  plots)  
34 for BR, IT1, US, RO and RU tablets. Shelf-life values calculated at 4, 25 and 40 °C for all  
35 paracetamol formulations.  
36  
37  
38  
39

## 40 **References**

- 41  
42  
43 [1] A.C. Santos, I. Pereira, M. Pereira-Silva, L. Ferreira, M. Caldas, M. Collado-González, M.  
44 Magalhães, A. Figueiras, A.J. Ribeiro, F. Veiga, Nanotechnology-based formulations for  
45 resveratrol delivery: Effects on resveratrol in vivo bioavailability and bioactivity, *Colloids*  
46 *Surf. B Biointerfaces*. 180 (2019) 127–140. <https://doi.org/10.1016/j.colsurfb.2019.04.030>.  
47 [2] A.C. Santos, I. Pereira, S. Reis, F. Veiga, M. Saleh, Y. Lvov, Biomedical potential of clay  
48 nanotube formulations and their toxicity assessment, *Expert Opin. Drug Deliv.* 16 (2019)  
49 1169–1182. <https://doi.org/10.1080/17425247.2019.1665020>.  
50 [3] P. Sengupta, B. Chatterjee, R.K. Tekade, Current regulatory requirements and practical  
51 approaches for stability analysis of pharmaceutical products: A comprehensive review, *Int. J.*  
52 *Pharm.* 543 (2018) 328–344. <https://doi.org/10.1016/j.ijpharm.2018.04.007>.  
53 [4] A.C. Fisher, S.L. Lee, D.P. Harris, L. Buhse, S. Kozlowski, L. Yu, M. Kopcha, J. Woodcock,  
54 Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's  
55 Office of Pharmaceutical Quality, *Int. J. Pharm.* 515 (2016) 390–402.  
56 <https://doi.org/10.1016/j.ijpharm.2016.10.038>.  
57 [5] L.X. Yu, M. Kopcha, The future of pharmaceutical quality and the path to get there, *Int. J.*  
58 *Pharm.* 528 (2017) 354–359. <https://doi.org/10.1016/j.ijpharm.2017.06.039>.  
59  
60  
61  
62  
63  
64  
65



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [6] R. Capen, D. Christopher, P. Forenzo, K. Huynh-Ba, D. LeBlond, O. Liu, J. O'Neill, N. Patterson, M. Quinlan, R. Rajagopalan, J. Schwenke, W. Stroup, Evaluating Current Practices in Shelf Life Estimation, *AAPS PharmSciTech.* 19 (2018) 668–680. <https://doi.org/10.1208/s12249-017-0880-4>.
- [7] H.S. Yayé, L. Hassani, P.-H. Secrétan, M. Babiard, H. Aouati, A. Bellanger, P. Tilleul, N. Yagoubi, B. Do, I.B. Rietveld, Physical and chemical stability of a generic etoposide formulation as an alternative to etoposide phosphate, *J. Pharm. Biomed. Anal.* 178 (2020) 112896. <https://doi.org/10.1016/j.jpba.2019.112896>.
- [8] R. Capen, D. Christopher, P. Forenzo, C. Ireland, O. Liu, S. Lyapustina, J. O'Neill, N. Patterson, M. Quinlan, D. Sandell, J. Schwenke, W. Stroup, T. Tougas, On the Shelf Life of Pharmaceutical Products, *AAPS PharmSciTech.* 13 (2012) 911–918. <https://doi.org/10.1208/s12249-012-9815-2>.
- [9] K.C. Waterman, Understanding and Predicting Pharmaceutical Product Shelf-Life, in: K. Huynh-Ba (Ed.), *Handb. Stab. Test. Pharm. Dev.*, Springer New York, New York, NY, 2009: pp. 115–135. [https://doi.org/10.1007/978-0-387-85627-8\\_6](https://doi.org/10.1007/978-0-387-85627-8_6).
- [10] R. Maheshwari, P. Todke, N. Soni, N. Raval, P.K. Deb, B. Amarji, N.V. Anil Kumar Ravipati, R.K. Tekade, Stability and Degradation Studies for Drug and Drug Product, in: *Dos. Form Des. Consid.*, Elsevier, 2018: pp. 225–257. <https://doi.org/10.1016/B978-0-12-814423-7.00007-1>.
- [11] A. Schiraldi, D. Fessas, Calorimetry and thermal analysis in food science: An updated review, *J. Therm. Anal. Calorim.* 138 (2019) 2721–2732. <https://doi.org/10.1007/s10973-019-08166-z>.
- [12] J. Li, J. Liu, X. Sun, Y. Liu, The mathematical prediction model for the oxidative stability of vegetable oils by the main fatty acids composition and thermogravimetric analysis, *LWT.* 96 (2018) 51–57. <https://doi.org/10.1016/j.lwt.2018.05.003>.
- [13] I. Blanco, Lifetime Prediction of Polymers: To Bet, or Not to Bet—Is This the Question?, *Materials.* 11 (2018). <https://doi.org/10.3390/ma11081383>.
- [14] A.J. de Jesus Silva, M.M. Contreras, C.R. Nascimento, M.F. da Costa, Kinetics of thermal degradation and lifetime study of poly(vinylidene fluoride) (PVDF) subjected to bioethanol fuel accelerated aging, *Heliyon.* 6 (2020) e04573. <https://doi.org/10.1016/j.heliyon.2020.e04573>.
- [15] A. Plota, A. Masek, Lifetime Prediction Methods for Degradable Polymeric Materials—A Short Review, *Materials.* 13 (2020). <https://doi.org/10.3390/ma13204507>.
- [16] M. Juhász, Y. Kitahara, S. Takahashi, T. Fujii, Thermal stability of vitamin C: Thermogravimetric analysis and use of total ion monitoring chromatograms, *J. Pharm. Biomed. Anal.* 59 (2012) 190–193. <https://doi.org/10.1016/j.jpba.2011.10.011>.
- [17] S.M. Jusu, J.D. Obayemi, A.A. Salifu, C.C. Nwazojie, V. Uzonwanne, O.S. Odusanya, W.O. Soboyejo, Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer, *Sci. Rep.* 10 (2020) 14188. <https://doi.org/10.1038/s41598-020-71129-0>.
- [18] D. Primavessy, N.G. Türeli, M. Schneider, Influence of different stabilizers on the encapsulation of desmopressin acetate into PLGA nanoparticles, *Eur. J. Pharm. Biopharm.* 118 (2017) 48–55. <https://doi.org/10.1016/j.ejpb.2016.12.003>.
- [19] M. Brusnikina, O. Silyukov, M. Chislov, T. Volkova, A. Proshin, I. Terekhova, New water-soluble dosage forms of 1,2,4-thiadiazole derivative on the basis of inclusion complexes with cyclodextrins, *J. Therm. Anal. Calorim.* 127 (2017) 1815–1824. <https://doi.org/10.1007/s10973-016-5955-z>.
- [20] I. Kritskiy, T. Volkova, A. Surov, I. Terekhova,  $\gamma$ -Cyclodextrin-metal organic frameworks as efficient microcontainers for encapsulation of leflunomide and acceleration of its transformation into teriflunomide, *Carbohydr. Polym.* 216 (2019) 224–230. <https://doi.org/10.1016/j.carbpol.2019.04.037>.

- 1 [21] L. Lisuzzo, G. Cavallaro, S. Milioto, G. Lazzara, Halloysite Nanotubes Coated by Chitosan for  
2 the Controlled Release of Khellin, *Polymers*. 12 (2020).  
3 <https://doi.org/10.3390/polym12081766>.
- 4 [22] L. Lisuzzo, G. Cavallaro, P. Pasbakhsh, S. Milioto, G. Lazzara, Why does vacuum drive to the  
5 loading of halloysite nanotubes? The key role of water confinement, *J. Colloid Interface Sci.*  
6 547 (2019) 361–369. <https://doi.org/10.1016/j.jcis.2019.04.012>.
- 7 [23] A. Panchal, G. Fakhrullina, R. Fakhrullin, Y. Lvov, Self-assembly of clay nanotubes on hair  
8 surface for medical and cosmetic formulations, *Nanoscale*. 10 (2018) 18205–18216.  
9 <https://doi.org/10.1039/C8NR05949G>.
- 10 [24] A.C. Santos, A. Panchal, N. Rahman, M. Pereira-Silva, I. Pereira, F. Veiga, Y. Lvov,  
11 Evolution of Hair Treatment and Care: Prospects of Nanotube-Based Formulations,  
12 *Nanomaterials*. 9 (2019). <https://doi.org/10.3390/nano9060903>.
- 13 [25] A. Stavitskaya, S. Batasheva, V. Vinokurov, G. Fakhrullina, V. Sangarov, Y. Lvov, R.  
14 Fakhrullin, Antimicrobial Applications of Clay Nanotube-Based Composites, *Nanomaterials*.  
15 9 (2019). <https://doi.org/10.3390/nano9050708>.
- 16 [26] T. Taroni, S. Cauteruccio, R. Vago, S. Franchi, N. Barbero, E. Licandro, S. Ardizzone, D.  
17 Meroni, Thiahelicene-grafted halloysite nanotubes: Characterization, biological studies and pH  
18 triggered release, *Appl. Surf. Sci.* 520 (2020) 146351.  
19 <https://doi.org/10.1016/j.apsusc.2020.146351>.
- 20 [27] R. Yendluri, D.P. Otto, M.M.D. Villiers, V. Vinokurov, Y.M. Lvov, Application of halloysite  
21 clay nanotubes as a pharmaceutical excipient, *Int. J. Pharm.* 521 (2017) 267–273.  
22 <https://doi.org/10.1016/j.ijpharm.2017.02.055>.
- 23 [28] M. Catauro, A. Dell’Era, S.V. Cipriotti, Synthesis, structural, spectroscopic and  
24 thermoanalytical study of sol–gel derived SiO<sub>2</sub>–CaO–P<sub>2</sub>O<sub>5</sub> gel and ceramic materials,  
25 *Thermochim. Acta*. 625 (2016) 20–27. <https://doi.org/10.1016/j.tca.2015.12.004>.
- 26 [29] M.A. Darji, R.M. Lalge, S.P. Marathe, T.D. Mulay, T. Fatima, A. Alshammari, H.K. Lee,  
27 M.A. Repka, S. Narasimha Murthy, Excipient Stability in Oral Solid Dosage Forms: A  
28 Review, *AAPS PharmSciTech*. 19 (2018) 12–26. <https://doi.org/10.1208/s12249-017-0864-4>.
- 29 [30] P. Zarnpi, T. Flanagan, E. Meehan, J. Mann, J. Østergaard, N. Fotaki, Biopharmaceutical  
30 implications of excipient variability on drug dissolution from immediate release products, *Eur.*  
31 *J. Pharm. Biopharm.* 154 (2020) 195–209. <https://doi.org/10.1016/j.ejpb.2020.07.014>.
- 32 [31] K. Krükle-Bērziņa, A. Actiņš, The effect of excipients on the stability and phase transition rate  
33 of xylazine hydrochloride and zopiclone, *J. Pharm. Biomed. Anal.* 107 (2015) 168–174.  
34 <https://doi.org/10.1016/j.jpba.2014.12.031>.
- 35 [32] N. Veronica, C.V. Liew, P.W.S. Heng, Insights on the role of excipients and tablet matrix  
36 porosity on aspirin stability, *Int. J. Pharm.* 580 (2020) 119218.  
37 <https://doi.org/10.1016/j.ijpharm.2020.119218>.
- 38 [33] J.F. Preuss, C.E. Goddard, R.C. Clarke, P.R. Platt, P.H. Sadleir, Anaphylaxis to intravenous  
39 paracetamol containing povidone. A case report and narrative review of excipient allergy  
40 related to anaesthesia, *Anaesth. Intensive Care*. 48 (2020) 404–408.  
41 <https://doi.org/10.1177/0310057X20940318>.
- 42 [34] E.A.K. Palomäki, T. Lipiäinen, C.J. Strachan, J.K. Yliruusi, Effect of trehalose and melibiose  
43 on crystallization of amorphous paracetamol, *Int. J. Pharm.* 590 (2020) 119878.  
44 <https://doi.org/10.1016/j.ijpharm.2020.119878>.
- 45 [35] H.A. Bicalho, R.D.F. Rios, I. Binatti, J.D. Ardisson, A.J. Howarth, R.M. Lago, A.P.C.  
46 Teixeira, Efficient activation of peroxy monosulfate by composites containing iron mining  
47 waste and graphitic carbon nitride for the degradation of acetaminophen, *J. Hazard. Mater.* 400  
48 (2020) 123310. <https://doi.org/10.1016/j.jhazmat.2020.123310>.
- 49 [36] Lucas-Granados Bianca, Sanchez-Tovar Rita, Fernandez-Domene Ramon, Garcia-Anton Jose,  
50 A Ph Study for the Degradation of Acetaminophen with Iron Oxide Nanostructures, *Chem.*  
51 *Eng. Trans.* 73 (2019) 139–144. <https://doi.org/10.3303/CET1973024>.
- 52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- [37] R. Katal, M. Salehi, M.H. Davood Abadi Farahani, S. Masudy-Panah, S.L. Ong, J. Hu, Preparation of a New Type of Black TiO<sub>2</sub> under a Vacuum Atmosphere for Sunlight Photocatalysis, *ACS Appl. Mater. Interfaces*. 10 (2018) 35316–35326. <https://doi.org/10.1021/acsami.8b14680>.
- [38] B. Zimmermann, G. Baranović, Thermal analysis of paracetamol polymorphs by FT-IR spectroscopies, *J. Pharm. Biomed. Anal.* 54 (2011) 295–302. <https://doi.org/10.1016/j.jpba.2010.08.023>.
- [39] I. Jendrzewska, T. Goryczka, E. Pietrasik, J. Klimontko, J. Jampilek, X-ray and Thermal Analysis of Selected Drugs Containing Acetaminophen, *Molecules*. 25 (2020). <https://doi.org/10.3390/molecules25245909>.
- [40] V. Bertolino, G. Cavallaro, G. Lazzara, S. Milioto, F. Parisi, Halloysite nanotubes sandwiched between chitosan layers: novel bionanocomposites with multilayer structures, *New J Chem*. 42 (2018) 8384–8390. <https://doi.org/10.1039/C8NJ01161C>.
- [41] M. Erceg, I. Krešić, M. Jakić, B. Andričić, Kinetic analysis of poly(ethylene oxide)/lithium montmorillonite nanocomposites, *J. Therm. Anal. Calorim.* 127 (2017) 789–797. <https://doi.org/10.1007/s10973-016-5413-y>.
- [42] M. Makaremi, P. Pasbakhsh, G. Cavallaro, G. Lazzara, Y.K. Aw, S.M. Lee, S. Milioto, Effect of Morphology and Size of Halloysite Nanotubes on Functional Pectin Bionanocomposites for Food Packaging Applications, *ACS Appl. Mater. Interfaces*. 9 (2017) 17476–17488. <https://doi.org/10.1021/acsami.7b04297>.
- [43] S. Rehman, S. Akram, A. Kanellopoulos, A. Elmarakbi, P.G. Karagiannidis, Development of new graphene/epoxy nanocomposites and study of cure kinetics, thermal and mechanical properties, *Thermochim. Acta*. 694 (2020) 178785. <https://doi.org/10.1016/j.tca.2020.178785>.
- [44] M. Jakić, N.S. Vrandečić, M. Erceg, The influence of poly(ethylene glycol) on thermal properties of poly(vinyl chloride)/poly(ethylene oxide) blends, *J. Therm. Anal. Calorim.* 127 (2017) 663–674. <https://doi.org/10.1007/s10973-016-5768-0>.
- [45] M. Jakić, N. Stipanelov Vrandečić, M. Erceg, Thermal degradation of poly(3-hydroxybutyrate)/poly(ethylene oxide) blends: Thermogravimetric and kinetic analysis, *Eur. Polym. J.* 81 (2016) 376–385. <https://doi.org/10.1016/j.eurpolymj.2016.06.024>.
- [46] M. Knorr, M. Icker, A. Efimova, P. Schmidt, Reactivity of Ionic Liquids: Studies on Thermal Decomposition Behavior of 1-Butyl-3-methylimidazolium Tetrafluoroborate, *Thermochim. Acta*. 694 (2020) 178786. <https://doi.org/10.1016/j.tca.2020.178786>.
- [47] M.L. Williams, J.S. Dickmann, M.E. McCorkill, J.C. Hassler, E. Kiran, The kinetics of thermal decomposition of 1-alkyl-3-methylimidazolium chloride ionic liquids under isothermal and non-isothermal conditions, *Thermochim. Acta*. 685 (2020) 178509. <https://doi.org/10.1016/j.tca.2020.178509>.
- [48] I. Mucha, P. Baranowski, A. Owczarek, M. Gajda, J. Pluta, A. Górniak, P. Niklewicz, B. Karolewicz, Thermal stability and decompositions kinetics under non-isothermal conditions of imatinib mesylate  $\alpha$  form, *J. Pharm. Biomed. Anal.* 129 (2016) 9–14. <https://doi.org/10.1016/j.jpba.2016.06.032>.
- [49] I. Badran, A.D. Manasrah, A. Hassan, N.N. Nassar, Kinetic study of the thermo-oxidative decomposition of metformin by isoconversional and theoretical methods, *Thermochim. Acta*. 694 (2020) 178797. <https://doi.org/10.1016/j.tca.2020.178797>.
- [50] I. Blanco, L. Abate, M.L. Antonelli, F.A. Bottino, The regression of isothermal thermogravimetric data to evaluate degradation Ea values of polymers: A comparison with literature methods and an evaluation of lifetime predictions reliability. Part II, *Polym. Degrad. Stab.* 98 (2013) 2291–2296. <https://doi.org/10.1016/j.polymdegradstab.2013.08.012>.
- [51] G. Cavallaro, A. Agliolo Gallitto, L. Lisuzzo, G. Lazzara, Comparative study of historical woods from XIX century by thermogravimetry coupled with FTIR spectroscopy, *Cellulose*. 26 (2019) 8853–8865. <https://doi.org/10.1007/s10570-019-02688-3>.

- 1 [52] S. Vecchio Cipriotti, M. Catauro, F. Bollino, R. Tuffi, Thermal behavior and dehydration  
2 kinetic study of SiO<sub>2</sub>/PEG hybrid gel glasses, *Polym. Eng. Sci.* 57 (2017) 606–612.  
3 <https://doi.org/10.1002/pen.24561>.
- 4 [53] D. Jelić, T. Liavitskaya, S. Vyazovkin, Thermal stability of indomethacin increases with the  
5 amount of polyvinylpyrrolidone in solid dispersion, *Thermochim. Acta.* 676 (2019) 172–176.  
6 <https://doi.org/10.1016/j.tca.2019.04.011>.
- 7 [54] I. Blanco, L. Abate, F.A. Bottino, Mono substituted octaphenyl POSSs: The effects of  
8 substituents on thermal properties and solubility, *Thermochim. Acta.* 655 (2017) 117–123.  
9 <https://doi.org/10.1016/j.tca.2017.06.019>.
- 10 [55] L. Lisuzzo, G. Cavallaro, S. Milioto, G. Lazzara, Effects of halloysite content on the thermo-  
11 mechanical performances of composite bioplastics, *Appl. Clay Sci.* 185 (2020) 105416.  
12 <https://doi.org/10.1016/j.clay.2019.105416>.
- 13 [56] X. Liu, J. Jiang, H. Zhang, M. Li, Y. Wu, L. Guo, W. Wang, P. Duan, W. Zhang, Z. Zhang,  
14 Thermal stability and microstructure of metakaolin-based geopolymer blended with rice husk  
15 ash, *Appl. Clay Sci.* 196 (2020) 105769. <https://doi.org/10.1016/j.clay.2020.105769>.
- 16 [57] A. Ziaee, S. O’Dea, A. Howard-Hildige, L. Padrela, C. Potter, J. Iqbal, A.B. Albadarin, G.  
17 Walker, E.J. O’Reilly, Amorphous solid dispersion of ibuprofen: A comparative study on the  
18 effect of solution based techniques, *Int. J. Pharm.* 572 (2019) 118816.  
19 <https://doi.org/10.1016/j.ijpharm.2019.118816>.
- 20 [58] I. Ledeti, M. Romanescu, D. Cîrcioban, A. Ledeti, G. Vlase, T. Vlase, O. Suci, M. Murariu,  
21 S. Olariu, P. Matusz, V. Buda, D. Piciu, Stability and Compatibility Studies of Levothyroxine  
22 Sodium in Solid Binary Systems—Instrumental Screening, *Pharmaceutics.* 12 (2020).  
23 <https://doi.org/10.3390/pharmaceutics12010058>.
- 24 [59] H.L. Friedman, Kinetics of thermal degradation of char-forming plastics from  
25 thermogravimetry. Application to a phenolic plastic, *J. Polym. Sci. Part C Polym. Symp.* 6  
26 (2007) 183–195. <https://doi.org/10.1002/polc.5070060121>.
- 27 [60] H.E. Kissinger, Variation of peak temperature with heating rate in differential thermal  
28 analysis, *J. Res. Natl. Bur. Stand.* 57 (1956) 217. <https://doi.org/10.6028/jres.057.026>.
- 29 [61] S. Vyazovkin, A.K. Burnham, J.M. Criado, L.A. Pérez-Maqueda, C. Popescu, N. Sbirrazzuoli,  
30 ICTAC Kinetics Committee recommendations for performing kinetic computations on thermal  
31 analysis data, *Thermochim. Acta.* 520 (2011) 1–19. <https://doi.org/10.1016/j.tca.2011.03.034>.
- 32 [62] J.M. Criado, J. Málek, A. Ortega, Applicability of the master plots in kinetic analysis of non-  
33 isothermal data, *Thermochim. Acta.* 147 (1989) 377–385. [https://doi.org/10.1016/0040-6031\(89\)85192-5](https://doi.org/10.1016/0040-6031(89)85192-5).
- 34 [63] S. Vyazovkin, Isoconversional Kinetics, in: *Handb. Therm. Anal. Calorim.*, Elsevier, 2008: pp.  
35 503–538. [https://doi.org/10.1016/S1573-4374\(08\)80016-7](https://doi.org/10.1016/S1573-4374(08)80016-7).
- 36 [64] P. Das, P. Tiwari, Thermal degradation kinetics of plastics and model selection, *Thermochim.*  
37 *Acta.* 654 (2017) 191–202. <https://doi.org/10.1016/j.tca.2017.06.001>.
- 38 [65] D. Raghuvanshi, G. Nkepan, A. Hussain, H. Yari, V. Awasthi, Stability study on an anti-  
39 cancer drug 4-(3,5-bis(2-chlorobenzylidene)-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid  
40 (CLEFMA) using a stability-indicating HPLC method, *J. Pharm. Anal.* 7 (2017) 1–9.  
41 <https://doi.org/10.1016/j.jpha.2016.09.004>.
- 42 [66] W. Zhu, X. Chen, L. Yuan, J. Wu, J. Yao, Degradation Kinetics and Shelf Life of N-  
43 acetylneuraminic Acid at Different pH Values, *Molecules.* 25 (2020).  
44 <https://doi.org/10.3390/molecules25215141>.
- 45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65